The candidate will be working to develop ubiquitin-independent protein degraders to overcome HER2+ targeted therapy resistance. The global objective of this project is to achieve ubiquitin independent Protacs that directly interact with proteasomal-associated factors to induce the degradation of proteins involved in breast cancer HER2+ targeted therapy resistance with the ultimate goal of their use at a translational level.
What do we look for?
Conditions:
– PhD thesis defended at the time of deadline for applications (11th September 2024).
– Max. 8 years experience in research, from the date of the award of their PhD degree.
Exception: For nationals or long-term residents of EU Member States or Horizon Europe Associated Countries who wish to reintegrate to Europe, years of experience in research in third countries will not be counted.
– Must not have resided or carried out main activity in Spain for more than 12 months between 11th September 2021 and 11th September 2024.
Deadline: 7th July 2024
Més posts de Recerca
Cap comentari:
Publica un comentari a l'entrada